A bio-based, multi-functional PHA coating technology that delivers enhanced mechanical strength, moisture and oxygen barrier performance, and antimicrobial functionality for sustainable food packaging applications.
This solution introduces hydrophobically modified polyhydroxyalkanoate (HM PHA) coatings engineered to overcome the traditional limitations of PHA materials, including brittleness, low impact resistance, and insufficient barrier properties. By incorporating hydrophobic moieties into the PHA matrix, the technology enables thin-film designs that maintain high oxygen and water vapor barrier performance while reducing material usage and energy input. The coatings can be functionalized with antioxidant, antimicrobial, and UV-resistant properties, making them a compelling alternative to conventional petroleum-based packaging films. The technology targets the food packaging industry, where demand is growing for compostable, high-performance materials that do not compromise product protection or shelf life.
Key features:
The technology has been validated through comprehensive characterization, including electron paramagnetic resonance (EPR) spectroscopy, turbidity, surface tension, viscosity, and fluorescence measurements across varying pH conditions and concentrations. Mechanical performance, barrier properties, and functional attributes have been tested in laboratory-scale film studies. Future validation will focus on aqueous PHA dispersion characterization via electroacoustic measurements for particle size and zeta potential, SEM surface morphology analysis of coated substrates, oxygen and water permeability testing, and evaluation of residual antimicrobial effects on compostability. The technology is positioned for pilot-scale demonstration and industry collaboration to advance toward commercial deployment.
Columbia University is a comprehensive private research university in New York City, combining an Ivy League academic profile with globally engaged scholarship and professional education. Its integration with a major hospital system through Columbia University Irving Medical Center and NewYork-Presbyterian enables clinical collaboration, access to diverse patient populations, and regulated studies at scale. State-of-the-art laboratories and shared core facilities across the Morningside and Manhattanville campuses support co-located industry projects, while proximity to New York’s finance, media, and healthcare ecosystems streamlines talent pipelines and pilot deployments. Industry engages via sponsored research, affiliate programs, executive education, and convenings that connect faculty expertise with corporate R&D priorities. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and DoD, alongside New York State and philanthropic sources. Columbia Technology Ventures provides IP management, licensing, startup support, and translational funding mechanisms that lower barriers to commercialization.